Shippeo Tops 103% Annual Growth, Becomes World's Most Recommended Real-time Transportation Visibility Provider
Shippeo, a global leader and European specialist in real-time transportation visibility, announced today 103% year-on-year growth in subscription revenues and 181% net retention rate. The visibility solutions provider maintains the fastest growing customer base in Europe, having expanded its presence globally with the acquisition of several new high-profile customers currently being deployed in North America, Latin America, and APAC.
Since January, Shippeo has welcomed several new large international brands, including Coca-Cola HBC, one of the largest strategic bottling partners of The Coca-Cola Company; Nexans, a global player in energy transition; XPO Logistics, an American freight transportation company; and Woco Group, a global automotive component specialist, who supplies major OEMs.
A number of other category-leading brands have also chosen Shippeo’s real-time visibility solution, including Sappi, a leading producer of coated graphic paper, packaging and specialty papers; Conad, an Italian retail brand operating one of the largest supermarket chains in Italy; Fnac Darty Group, a French multinational electrical retailing company; Studio Moderna, an e-commerce company primarily operating across Central and Eastern Europe; and IDS, a Dutch 4PL logistics control tower specialist.
“Our very high net retention rate is a direct result of customers choosing to take fuller advantage of our expanding product portfolio, which now includes dock visibility and paperless visibility. Our ocean visibility has also become particularly popular as factors including Covid, the Suez blockage, and a global shortage of containers only intensifies the focus on the performance of this critical transport mode,” says Lucien Besse, COO of Shippeo.
“Shippeo has been recognized with a 98% recommendation rate on Gartner Peer Insights by our customers as at October 13, 2021*. I’m particularly proud of this achievement. Nothing is more important to us than delivering value to our customers and this is a fantastic result,” says Besse.
Shippeo’s team has expanded to over 230, with more than 90 new team members joining since January. Shippeo is on track to have more than doubled its staff year-on-year by the end of 2021. In addition, a number of senior profiles joined the company, including Nicolas Doucet, Strategic Alliance Director, previously at PTV Group; Guy-Pascal Bourlard, Head of Quality Assurance, previously at Amazon; Olivier Marcellin, Product Director, previously at Criteo; Marius Neuhäuser, Head of Solution Consulting, Alessandro De Martini, Business Development Director Italy, previously Country Manager at Transporeon and Bas Kramer, Business Development Director Benelux.
Furthermore, Shippeo is now expanding its operations into North America. As part of this strategic expansion, the company has welcomed Christopher Mazza as Senior Vice President, International Growth who will be responsible for leading the company’s activities in the region and growing Shippeo’s customer base. Christopher has extensive experience in the transportation and logistics industry, having participated in the creation of ClearMetal where he played an integral role in business development before joining project44 following the company's acquisition.
Recently the company announced new strategic partnerships with Savoye, a leading designer and integrator of complete supply chain solutions, and Tesisquare, a leading provider of supply chain execution applications. Shippeo has also partnered with Siemens DL, a leading IT provider in global supply chain management solutions.
The collaborations aim to make it easier for customers to overcome transport management challenges by leveraging deep TMS integrations, making it simple to take advantage of real-time visibility’s many benefits.
“We’re incredibly proud of the momentum we’re experiencing and the fact that we’ve maintained 0% customer churn throughout the year,” says Besse. “It’s really thanks to our extremely dedicated teams, our holistic customer-centric approach and a focus on the quality of our solution implementations, relationships and accelerated time to value for customers.”
Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of
Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005600/en/
Contact information
Shippeo
Audrey Emanuel
audrey.emanuel@shippeo.com
+33 6 17 33 36 47
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom